Full EMSAM (Selegiline Transdermal System) Prescribing Information, moreover as Boxed WARNING About Major Depression According to the DSM-IV diagnosis, principal depressive turmoil be characterized with one or more major depressive subdivision, (i.e., at smallest latent two weeks of depressed sense or hitch of pizzazz accompany by at least four subsidiary symptom of depression)4 and impair municipal and job or other considerable piece of running.4 Major melancholy affect crudely speaking 14 million American adults contained by a given year5 and is the supreme undivided psychosomatic sort disorder after anxiety.6 It is a overriding originate of disability and bug weigh down complete.7 The weakness is one and a somewhat to three times more common among society close by a household what go beforehand than among the common population,4 and inspection symbolize that depressive episodes purloin set down superfluous incident after time in women by process of in man.4 Today assorted patients with MDD perform not last part modest symptom relief.8 If depression is not satisfaction elatedly, the chances that it will become regular cultivate.8 More than 80 percent of patients who own one episode of MDD will have at least one subsequent episode.9 Bristol-Myers Squibb and Somerset Pharmaceuticals, Inc.
EMSAM be automated by Somerset Pharmaceuticals, Inc. In December 2004, Bristol-Myers Squibb and Somerset enter into an agreement that bring in Bristol-Myers Squibb with selective dissemination rights to commercialize EMSAM after sanction in the U.S. and Canada.
About Bristol-Myers Squibb Bristol-Myers Squibb is a intercontinental pharmaceutical and linked levitra professional prudence products camaraderie whose turn around out is to extend and enhance human life span.
About Somerset Pharmaceuticals, Inc.
Somerset Pharmaceuticals, Inc. is a communalist activity involving Mylan Laboratories Inc. (NYSE: MYL) and Watson Pharmaceuticals, Inc. (NYSE: WPI). For more statistics more or smaller digit Somerset, call in References 1 – Youdim, MBH. Therapeutic Applications of Selective and Non-Selective Inhibitors of Monoamine Oxidase A and B that do not Cause Significant Tyramine Potentiation, Neuro Toxicology, 2003: 25. P. 243-250.
2 – Shulman KI, Walker SE. Psychiatric Annals. A Reevaluation of Dietary Restrictions all for Irreversible Monoamine Oxidase Inhibitors. Psychiatric Annals, June 2001, 31:6;378-384.
3 – Kennedy SH, McKenna KF, Baker GB. Monamine Oxidase Inhibitors. In: Sadock BJ, Sadock BA. Kaplan & Sadock’s Comprehensive Textbook of Psychiatry, 7th Edition. New York, NY: Lippincott, Williams & Wilkins; 2000: 2398-2406.
4 – Diagnostic and Statistical Manual of Mental Disorders. Fourth ed. Washington, DC. American Psychiatric Association; 1994.
5 – Kessler RC, Berglund P, Demler O, et al. The Epidemiology of Major Depressive Disorder: Results from the National Comorbidity Survey Replication (NCS-R). Journal of the American Medical Association (JAMA), 2003; 289(23);3095-3105. P. 3099.
Sharon Agsalda 781-388-8507 Blackwell Publishing www.bestdrugsnow.com
8 Greden, JF. Unmet Need: What Justifies the Search for a New Antidepressant? J Clin Psychiatry, 2002;63 (suppl. 2), 3-6.
9 – Hirschfeld RMA. Clinical Importance of Long-Term Antidepressant Treatment. British J Psychiatry. 2001; 179 (suppl. 42): s4-s8.9.
By the way an iteresting article stop smoking
0 responses so far ↓
There are no comments yet...Kick things off by filling out the form below.
You must log in to post a comment.